APIXORA Strategic Investment Partner Invitation
We are looking for partners to build a new business infrastructure for the pharmaceutical raw materials industry together
APIXORA is a business platform specializing in pharmaceutical raw materials that connects Korean pharmaceutical companies with domestic and international manufacturers and suppliers of Active Pharmaceutical Ingredients (API), API Intermediates, and Pharmaceutical Excipients.
From finding products and manufacturers to comparing supplier proposals, reviewing quality and regulatory documents, contracting, registration, commercial supply, and post-supply management, we connect every step so that pharmaceutical raw material businesses lead to real results.
Going beyond simple product search or company introductions, APIXORA aims to grow into a pharmaceutical raw material business infrastructure that Korean pharmaceutical companies and global manufacturers can trust.
APIXORA Is Already Underway in the Market
APIXORA launched its supplier beta service on June 25, 2026, and officially opened its service to Korean pharmaceutical companies on August 31 of the same year.
Since the official launch, participation from Korean pharmaceutical companies and global manufacturers and suppliers has expanded rapidly, and more than 150 pharmaceutical industry professionals from Korea and abroad are now APIXORA members. We have also built a supply base of more than 2,000 products, including APIs, intermediates, and pharmaceutical excipients, and new member and product registrations continue to grow.
Real sourcing requests and RFQs from Korean pharmaceutical companies are being issued on the platform, while overseas suppliers are submitting Proposals and product matching is under way.
Having completed platform development and market entry, APIXORA is moving into the commercialization stage, where real demand and supply are connected.
Beyond Matching, to Business Success
A pharmaceutical raw material business is not complete simply by finding a manufacturer.
Even after identifying a competitive manufacturing source, specialized work continues: negotiating price and supply terms, sample and quality evaluation, regulatory document review, contracting, registration, commercial supply, and post-supply management.
APIXORA supports this entire process with more than 20 years of experience in API manufacturing, quality, regulatory affairs, sourcing, and business development accumulated under its CEO, together with a network of expert partners in Korea and abroad.
Through this, we provide Korean pharmaceutical companies with a more efficient and transparent global sourcing environment, and give overseas manufacturers the opportunity to enter and commercialize in the Korean market.
Now Preparing for Greater Growth
APIXORA's core platform and business foundation are already in place.
Going forward, building on our accumulated product and member company data, we aim to increase platform utilization, turn more matches into actual contracts and commercial supply, and grow beyond Korea into a global pharmaceutical raw material business platform.
We plan to accelerate the next stage of growth through strategic investment.
- Continued expansion of our network of Korean pharmaceutical companies and global manufacturers, and of product data
- Enhancement of data analytics, workflow automation, and user convenience on the operating platform
- Stronger commercialization of AI matching and anti-circumvention technology based on filed patents
- Phased recruitment of regulatory, quality, technical, and business development experts to extend existing commercialization capabilities
- Organizational expansion of expertise, including experience with MFDS review and regulatory response
- Stronger marketing and global partnerships to expand domestic market share and enter overseas markets
This investment is not funding to build a new business from scratch.
It is a growth investment that enables APIXORA, which has already completed development and market entry, to accelerate its growth and convert accumulated business opportunities into real results and corporate value.
Seeking Partners to Grow With, Not Just Capital
Rather than investors who simply provide capital, APIXORA hopes to meet strategic partners who share our view of the potential for change in the pharmaceutical raw materials industry and APIXORA's long-term vision.
Those who look together at the market problems APIXORA aims to solve and the platform's growth potential, and who will build long-term corporate value with us, can become even more meaningful partners.
We will engage openly with individuals and companies alike: those with experience or networks in the pharmaceutical and biotech industries, global supply chains, IT platforms, or company growth, as well as anyone who shares APIXORA's vision and potential.
Investment Inquiries and Meetings
APIXORA will hold discussions with strategic investment partners from September to October 2026.
If you are interested, please contact us at the email address below. Company and platform introduction materials, the business plan, investment structure, and detailed terms will be provided individually.
On-site meetings or in-person business presentations with the CEO are also available.
The specific investment structure, investment amount, corporate valuation, and equity terms will be presented and finalized through individual meetings and discussions.